These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21576431)

  • 21. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study.
    Frippiat F; Musuamba FT; Seidel L; Albert A; Denooz R; Charlier C; Van Bambeke F; Wallemacq P; Descy J; Lambermont B; Layios N; Damas P; Moutschen M
    J Antimicrob Chemother; 2015 Jan; 70(1):207-16. PubMed ID: 25216821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
    Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
    Louie A; Grasso C; Bahniuk N; Van Scoy B; Brown DL; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2646-54. PubMed ID: 20368395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.
    Wenzler E; Gotfried MH; Loutit JS; Durso S; Griffith DC; Dudley MN; Rodvold KA
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7232-9. PubMed ID: 26349830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
    Kuti JL; Florea NR; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2004 Jan; 24(1):8-15. PubMed ID: 14740783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
    Conte JE; Golden JA; Kelley MG; Zurlinden E
    Int J Antimicrob Agents; 2005 Dec; 26(6):449-56. PubMed ID: 16280244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
    Bulik CC; Christensen H; Li P; Sutherland CA; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2010 Feb; 54(2):804-10. PubMed ID: 19995927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
    Xiao AJ; Miller BW; Huntington JA; Nicolau DP
    J Clin Pharmacol; 2016 Jan; 56(1):56-66. PubMed ID: 26096377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
    Kong L; Tang Y; Zhang X; Lu G; Yu M; Shi Q; Wu X
    Ann Pharmacother; 2017 Nov; 51(11):970-975. PubMed ID: 28677407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
    Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro killing activity of meropenem versus imipenem against multiresistant nosocomial Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    J Chemother; 1995 Jun; 7(3):179-83. PubMed ID: 7562010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.
    Mohamed AF; Kristoffersson AN; Karvanen M; Nielsen EI; Cars O; Friberg LE
    J Antimicrob Chemother; 2016 May; 71(5):1279-90. PubMed ID: 26850719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individual meropenem epithelial lining fluid and plasma PK/PD target attainment.
    Rohani R; Yarnold PR; Scheetz MH; Neely MN; Kang M; Donnelly HK; Dedicatoria K; Nozick SH; Medernach RL; Hauser AR; Ozer EA; Diaz E; Misharin AV; Wunderink RG; Rhodes NJ
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0072723. PubMed ID: 37975660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
    Morinaga Y; Yanagihara K; Nakamura S; Yamamoto K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
    J Antimicrob Chemother; 2008 Dec; 62(6):1326-31. PubMed ID: 18835805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.
    Kristoffersson AN; David-Pierson P; Parrott NJ; Kuhlmann O; Lave T; Friberg LE; Nielsen EI
    Pharm Res; 2016 May; 33(5):1115-25. PubMed ID: 26786016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.
    Braune S; König C; Roberts JA; Nierhaus A; Steinmetz O; Baehr M; Kluge S; Langebrake C
    Crit Care; 2018 Jan; 22(1):25. PubMed ID: 29382394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation.
    Eguchi K; Kanazawa K; Shimizudani T; Kanemitsu K; Kaku M
    J Infect Chemother; 2010 Feb; 16(1):1-9. PubMed ID: 20072800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
    Lodise TP; Nau R; Kinzig M; Drusano GL; Jones RN; Sörgel F
    J Antimicrob Chemother; 2007 Nov; 60(5):1038-44. PubMed ID: 17785282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.